Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
38
TCRX Quote, Financials, Valuation and Earnings
Last price:
$1.07
Seasonality move
:
1.49%
Day range:
$0.98 - $1.07
52-week range:
$0.88 - $3.21
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
16.05x
P/B ratio:
0.42x
Volume:
626.7K
Avg. volume:
762.8K
1-year change:
-65.92%
Market cap:
$60.2M
Revenue:
$2.8M
EPS (TTM):
-$1.12
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TCRX
TScan Therapeutics, Inc.
|
$2M | -$0.20 | 191.73% | -6.91% | $6.00 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $2.20 | 98.51% | -58.59% | $491.92 |
|
GERN
Geron Corp.
|
$53.8M | -$0.03 | 7.03% | -8.38% | $3.60 |
|
GTBP
GT Biopharma, Inc.
|
-- | -- | -- | -- | $8.00 |
|
NVAX
Novavax, Inc.
|
$114.5M | -$0.32 | 2.21% | -8.63% | $12.78 |
|
XOMA
XOMA Royalty Corp.
|
$12.8M | $0.04 | 27.73% | -80.01% | $64.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TCRX
TScan Therapeutics, Inc.
|
$1.06 | $6.00 | $60.2M | -- | $0.00 | 0% | 16.05x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$400.59 | $491.92 | $52.9B | 1,665.65x | $0.00 | 0% | 16.43x |
|
GERN
Geron Corp.
|
$1.37 | $3.60 | $874.5M | -- | $0.00 | 0% | 4.97x |
|
GTBP
GT Biopharma, Inc.
|
$0.83 | $8.00 | $8.9M | -- | $0.00 | 0% | 59.35x |
|
NVAX
Novavax, Inc.
|
$6.83 | $12.78 | $1.1B | 3.86x | $0.00 | 0% | 1.09x |
|
XOMA
XOMA Royalty Corp.
|
$26.06 | $64.50 | $322.7M | 34.96x | $0.54 | 0% | 9.06x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TCRX
TScan Therapeutics, Inc.
|
39.9% | 3.110 | 92.58% | 6.32x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
92.22% | 1.279 | 4.61% | 2.37x |
|
GERN
Geron Corp.
|
50.25% | 1.700 | 28.73% | 4.76x |
|
GTBP
GT Biopharma, Inc.
|
-- | -0.510 | 4.06% | 1.98x |
|
NVAX
Novavax, Inc.
|
265.85% | 2.153 | 17.83% | 1.90x |
|
XOMA
XOMA Royalty Corp.
|
54.99% | 1.936 | 26.95% | 3.38x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TCRX
TScan Therapeutics, Inc.
|
$1.7M | -$37.1M | -48.24% | -71.23% | -1475.59% | -$33.9M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1B | $368M | 1.51% | 31.15% | 29.46% | $313M |
|
GERN
Geron Corp.
|
$45.9M | -$13.9M | -16.45% | -29.65% | -29.41% | -$13.5M |
|
GTBP
GT Biopharma, Inc.
|
-- | -$3.4M | -626.24% | -626.24% | -- | -$3.7M |
|
NVAX
Novavax, Inc.
|
$50.6M | -$79.4M | -- | -- | -112.72% | $105.8M |
|
XOMA
XOMA Royalty Corp.
|
$8.5M | -$1.3M | 7.44% | 17.31% | -14.22% | -$957K |
TScan Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns TCRX or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -1422.14% compared to TScan Therapeutics, Inc.'s net margin of 20.1%. TScan Therapeutics, Inc.'s return on equity of -71.23% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.
Company Gross Margin Earnings Per Share Invested Capital TCRXTScan Therapeutics, Inc.69.45% -$0.28 $239.6M ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B -
What do Analysts Say About TCRX or ALNY?
TScan Therapeutics, Inc. has a consensus price target of $6.00, signalling upside risk potential of 466.04%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $491.92 which suggests that it could grow by 22.8%. Given that TScan Therapeutics, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe TScan Therapeutics, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TCRXTScan Therapeutics, Inc.4 2 0 ALNYAlnylam Pharmaceuticals, Inc.14 7 0 -
Is TCRX or ALNY More Risky?
TScan Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.301, suggesting its less volatile than the S&P 500 by 69.879%.
-
Which is a Better Dividend Stock TCRX or ALNY?
TScan Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TScan Therapeutics, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TCRX or ALNY?
TScan Therapeutics, Inc. quarterly revenues are $2.5M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. TScan Therapeutics, Inc.'s net income of -$35.7M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, TScan Therapeutics, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,665.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TScan Therapeutics, Inc. is 16.05x versus 16.43x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCRXTScan Therapeutics, Inc.16.05x -- $2.5M -$35.7M ALNYAlnylam Pharmaceuticals, Inc.16.43x 1,665.65x $1.2B $251.1M
-
Which has Higher Returns TCRX or GERN?
Geron Corp. has a net margin of -1422.14% compared to TScan Therapeutics, Inc.'s net margin of -39.02%. TScan Therapeutics, Inc.'s return on equity of -71.23% beat Geron Corp.'s return on equity of -29.65%.
Company Gross Margin Earnings Per Share Invested Capital TCRXTScan Therapeutics, Inc.69.45% -$0.28 $239.6M GERNGeron Corp.97.13% -$0.03 $500M -
What do Analysts Say About TCRX or GERN?
TScan Therapeutics, Inc. has a consensus price target of $6.00, signalling upside risk potential of 466.04%. On the other hand Geron Corp. has an analysts' consensus of $3.60 which suggests that it could grow by 162.77%. Given that TScan Therapeutics, Inc. has higher upside potential than Geron Corp., analysts believe TScan Therapeutics, Inc. is more attractive than Geron Corp..
Company Buy Ratings Hold Ratings Sell Ratings TCRXTScan Therapeutics, Inc.4 2 0 GERNGeron Corp.3 1 1 -
Is TCRX or GERN More Risky?
TScan Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Geron Corp. has a beta of 0.567, suggesting its less volatile than the S&P 500 by 43.26%.
-
Which is a Better Dividend Stock TCRX or GERN?
TScan Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TScan Therapeutics, Inc. pays -- of its earnings as a dividend. Geron Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TCRX or GERN?
TScan Therapeutics, Inc. quarterly revenues are $2.5M, which are smaller than Geron Corp. quarterly revenues of $47.2M. TScan Therapeutics, Inc.'s net income of -$35.7M is lower than Geron Corp.'s net income of -$18.4M. Notably, TScan Therapeutics, Inc.'s price-to-earnings ratio is -- while Geron Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TScan Therapeutics, Inc. is 16.05x versus 4.97x for Geron Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCRXTScan Therapeutics, Inc.16.05x -- $2.5M -$35.7M GERNGeron Corp.4.97x -- $47.2M -$18.4M
-
Which has Higher Returns TCRX or GTBP?
GT Biopharma, Inc. has a net margin of -1422.14% compared to TScan Therapeutics, Inc.'s net margin of --. TScan Therapeutics, Inc.'s return on equity of -71.23% beat GT Biopharma, Inc.'s return on equity of -626.24%.
Company Gross Margin Earnings Per Share Invested Capital TCRXTScan Therapeutics, Inc.69.45% -$0.28 $239.6M GTBPGT Biopharma, Inc.-- -$0.83 $3M -
What do Analysts Say About TCRX or GTBP?
TScan Therapeutics, Inc. has a consensus price target of $6.00, signalling upside risk potential of 466.04%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 861.08%. Given that GT Biopharma, Inc. has higher upside potential than TScan Therapeutics, Inc., analysts believe GT Biopharma, Inc. is more attractive than TScan Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TCRXTScan Therapeutics, Inc.4 2 0 GTBPGT Biopharma, Inc.1 0 0 -
Is TCRX or GTBP More Risky?
TScan Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.367%.
-
Which is a Better Dividend Stock TCRX or GTBP?
TScan Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TScan Therapeutics, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TCRX or GTBP?
TScan Therapeutics, Inc. quarterly revenues are $2.5M, which are larger than GT Biopharma, Inc. quarterly revenues of --. TScan Therapeutics, Inc.'s net income of -$35.7M is lower than GT Biopharma, Inc.'s net income of -$3.1M. Notably, TScan Therapeutics, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TScan Therapeutics, Inc. is 16.05x versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCRXTScan Therapeutics, Inc.16.05x -- $2.5M -$35.7M GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M
-
Which has Higher Returns TCRX or NVAX?
Novavax, Inc. has a net margin of -1422.14% compared to TScan Therapeutics, Inc.'s net margin of -287.29%. TScan Therapeutics, Inc.'s return on equity of -71.23% beat Novavax, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TCRXTScan Therapeutics, Inc.69.45% -$0.28 $239.6M NVAXNovavax, Inc.71.9% -$1.25 $94.5M -
What do Analysts Say About TCRX or NVAX?
TScan Therapeutics, Inc. has a consensus price target of $6.00, signalling upside risk potential of 466.04%. On the other hand Novavax, Inc. has an analysts' consensus of $12.78 which suggests that it could grow by 87.08%. Given that TScan Therapeutics, Inc. has higher upside potential than Novavax, Inc., analysts believe TScan Therapeutics, Inc. is more attractive than Novavax, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TCRXTScan Therapeutics, Inc.4 2 0 NVAXNovavax, Inc.5 1 1 -
Is TCRX or NVAX More Risky?
TScan Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Novavax, Inc. has a beta of 2.305, suggesting its more volatile than the S&P 500 by 130.478%.
-
Which is a Better Dividend Stock TCRX or NVAX?
TScan Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TScan Therapeutics, Inc. pays -- of its earnings as a dividend. Novavax, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TCRX or NVAX?
TScan Therapeutics, Inc. quarterly revenues are $2.5M, which are smaller than Novavax, Inc. quarterly revenues of $70.4M. TScan Therapeutics, Inc.'s net income of -$35.7M is higher than Novavax, Inc.'s net income of -$202.4M. Notably, TScan Therapeutics, Inc.'s price-to-earnings ratio is -- while Novavax, Inc.'s PE ratio is 3.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TScan Therapeutics, Inc. is 16.05x versus 1.09x for Novavax, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCRXTScan Therapeutics, Inc.16.05x -- $2.5M -$35.7M NVAXNovavax, Inc.1.09x 3.86x $70.4M -$202.4M
-
Which has Higher Returns TCRX or XOMA?
XOMA Royalty Corp. has a net margin of -1422.14% compared to TScan Therapeutics, Inc.'s net margin of 52.48%. TScan Therapeutics, Inc.'s return on equity of -71.23% beat XOMA Royalty Corp.'s return on equity of 17.31%.
Company Gross Margin Earnings Per Share Invested Capital TCRXTScan Therapeutics, Inc.69.45% -$0.28 $239.6M XOMAXOMA Royalty Corp.90.59% $0.70 $239.9M -
What do Analysts Say About TCRX or XOMA?
TScan Therapeutics, Inc. has a consensus price target of $6.00, signalling upside risk potential of 466.04%. On the other hand XOMA Royalty Corp. has an analysts' consensus of $64.50 which suggests that it could grow by 147.51%. Given that TScan Therapeutics, Inc. has higher upside potential than XOMA Royalty Corp., analysts believe TScan Therapeutics, Inc. is more attractive than XOMA Royalty Corp..
Company Buy Ratings Hold Ratings Sell Ratings TCRXTScan Therapeutics, Inc.4 2 0 XOMAXOMA Royalty Corp.4 0 0 -
Is TCRX or XOMA More Risky?
TScan Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison XOMA Royalty Corp. has a beta of 0.941, suggesting its less volatile than the S&P 500 by 5.919%.
-
Which is a Better Dividend Stock TCRX or XOMA?
TScan Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XOMA Royalty Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.54 per share. TScan Therapeutics, Inc. pays -- of its earnings as a dividend. XOMA Royalty Corp. pays out 39.59% of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TCRX or XOMA?
TScan Therapeutics, Inc. quarterly revenues are $2.5M, which are smaller than XOMA Royalty Corp. quarterly revenues of $9.4M. TScan Therapeutics, Inc.'s net income of -$35.7M is lower than XOMA Royalty Corp.'s net income of $10.3M. Notably, TScan Therapeutics, Inc.'s price-to-earnings ratio is -- while XOMA Royalty Corp.'s PE ratio is 34.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TScan Therapeutics, Inc. is 16.05x versus 9.06x for XOMA Royalty Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCRXTScan Therapeutics, Inc.16.05x -- $2.5M -$35.7M XOMAXOMA Royalty Corp.9.06x 34.96x $9.4M $10.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
